A Phase I, open-label, multi-center study to evaluate the safety, tolerability, dosimetry andpreliminary activity of [177Lu]Lu-FF58 in patients with selected advanced solid tumors

The purpose of the study is to test the safety and dosing of the study drug, [ 177Lu]Lu-FF58, a radioligand therapy for patients with various types of cancers. The study will also test the ability to identify tumor lesions using the new imaging agent, [68Ga]Ga-FF58, a radioligand imaging agent, and to see if it is safe. Radioligands are a type of cancer medicine in which a radioactive particle is attached to a compound (FF58 in this study). The compound circulates through the bloodstream, binds to proteins found on tumor lesions, and exposes those tumor lesions to radiation. FF58 can be attached to either a radioactive particle used for imaging (gallium-68, or 68Ga) or another one used for therapy (lutetium-177, or 177Lu).

Are you Eligible? (Inclusion Criteria)

• Age ≥ 18 years old 2. You cannot have urinary incontinence (lack of bladder control) 3. You cannot have any serious uncontrolled infection